Grassley backs FDA “whistleblower”
Executive Summary
Senate Finance Committee Chairman Charles Grassley (R-Iowa) asks FDA in Nov. 29 letter to explain allegations that Office of Drug Safety Associate Director for Science David Graham, MD, will face compulsory reassignment or be fired for criticism of the agency at Vioxx hearing (1"The Pink Sheet" Nov. 22, 2004, p. 4). A Nov. 24 letter from Grassley calls for an HHS Office of Inspector General investigation of reports that two FDA managers sought to preemptively discredit Graham to a whistleblower protection organization. "It appears that these activities may have been coordinated by FDA management and may have involved the misuse of government resources," Grassley says...
You may also be interested in...
Crestor, Serevent Safety Issues Push Vioxx Out Of Spotlight In Senate Hearing
FDA's focus following the Senate Finance Committee hearing on the Vioxx withdrawal is on defending the safety of five other drugs challenged by one of its safety reviewers
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.